Neil Gagnon Purchases 6,496 Shares of CareDx, Inc. (CDNA) Stock
CareDx, Inc. (NASDAQ:CDNA) major shareholder Neil Gagnon bought 6,496 shares of the stock in a transaction on Thursday, September 7th. The shares were bought at an average price of $3.05 per share, for a total transaction of $19,812.80. Following the purchase, the insider now directly owns 916,546 shares in the company, valued at approximately $2,795,465.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Neil Gagnon also recently made the following trade(s):
- On Monday, August 28th, Neil Gagnon bought 21,448 shares of CareDx stock. The shares were bought at an average price of $2.77 per share, for a total transaction of $59,410.96.
- On Friday, August 25th, Neil Gagnon bought 35,119 shares of CareDx stock. The shares were bought at an average price of $2.92 per share, for a total transaction of $102,547.48.
- On Monday, July 24th, Neil Gagnon bought 1,486 shares of CareDx stock. The shares were bought at an average price of $1.23 per share, for a total transaction of $1,827.78.
- On Thursday, June 29th, Neil Gagnon bought 1,808 shares of CareDx stock. The shares were bought at an average price of $1.11 per share, for a total transaction of $2,006.88.
- On Friday, June 23rd, Neil Gagnon bought 63,120 shares of CareDx stock. The shares were bought at an average price of $1.10 per share, for a total transaction of $69,432.00.
CareDx, Inc. (NASDAQ CDNA) traded up 0.34% during trading on Friday, reaching $2.98. 267,268 shares of the company’s stock traded hands. The company has a 50 day moving average of $1.96 and a 200 day moving average of $1.49. CareDx, Inc. has a one year low of $0.76 and a one year high of $4.62. The firm’s market cap is $67.17 million.
CareDx (NASDAQ:CDNA) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). The business had revenue of $12.05 million during the quarter, compared to the consensus estimate of $11.87 million. CareDx had a negative return on equity of 85.68% and a negative net margin of 61.27%. Equities research analysts predict that CareDx, Inc. will post ($0.82) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Neil Gagnon Purchases 6,496 Shares of CareDx, Inc. (CDNA) Stock” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/10/neil-gagnon-purchases-6496-shares-of-caredx-inc-cdna-stock.html.
Several equities analysts have issued reports on CDNA shares. Zacks Investment Research upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. ValuEngine cut shares of CareDx from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Gagnon Securities LLC boosted its holdings in CareDx by 2.9% in the second quarter. Gagnon Securities LLC now owns 2,084,292 shares of the company’s stock worth $2,314,000 after acquiring an additional 57,954 shares in the last quarter. Royce & Associates LP boosted its holdings in CareDx by 23.5% in the first quarter. Royce & Associates LP now owns 526,472 shares of the company’s stock worth $737,000 after acquiring an additional 100,111 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new stake in CareDx in the second quarter worth about $212,000. 29.15% of the stock is owned by institutional investors and hedge funds.
CareDx, Inc is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Receive News & Stock Ratings for CareDx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx Inc. and related stocks with our FREE daily email newsletter.